TABLE OF CONTENTS

List of Figure……XI
List of Tables……XVIII
List of abbreviations and symbols……XIX
Preface……..XXI
Chapter I…….1
1. General introduction……..2
2. Types of NLBCs……..6
2.1 Liposomes…….....6
2.2 Niosome…….....8
2.3 Solid lipid nanoparticles (SLNs)…….....9
2.4 Nanostructured lipid carriers (NLCs)……..13
2.5 Lipid polymer hybrid nanoparticles (LPHNs)……14
3. Preparation methods of NLBCs……..16
3.1 Double emulsion method……..16
3.2 Solvent injection method……..18
3.3 Micro emulsion method ……....18
3.4 Ultra sonication method……. ……19
3.5 Spray-drying method…….....19
3.6 Emulsification solvent evaporation method…….....19
3.7 Supercritical fluid method……...20
3.8 Hot homogenoization method……..20
3.9 Cold homogenization method……..21
4. Stability and Drawbacks…….....22
5. Lyophilization (Freeze-drying)…….....24
6. Targeting moieties…….27
6.1 Transferrin receptor…….....30
6.2 Folate receptor…….....33
6.3 Hyaluronic acid…….....35
6.4 Aptamer…….....37
6.5 Peptide……....41

6.6 Growth factor as a target…….....45

6.7 Galactose……47

7. Challenges in the scale-up of lipid-nanomedicines manufacturing: from……..49 laboratories to industry

8. Objective and goal of the study……...51

9. References…….52

Chapter II……....65

1. Introduction…….....66

2. Material and methods…….....68

2.1 Materials…….68

2.2. Fabrication of Q laden NLBCs……69

2.3 Preparatin of N-acetyl-D-glucosylated Q-loaded NLBCs…….....70

2.4 *In vitro* fluorescence study using lectin-NADG nano bioconjugate……..71

2.5 Encapsulation efficiency and percentage of drug loading…….....72

2.6 Scanning Elecron microscopy(SEM) of nano-bioconjgate…….....72

2.7 Analysis of particle diameter & charge distribution…….....73

2.8 Infrared spectroscopy (IR) characteization of nano-bioconjugate.....73

2.9 X-ray characterization (XRD) of nano-bioconjugate…….....73

2.10 *In vitro* drug release study of nanobioconjugate…….....74

2.11 Cell culture and assessment of *in vitro* cell toxicity…….....74

2.12 Testing of statistical significance…….....75

2.13 Flow cytometry analysis……....75

3. Results and Discussions……..76

3.1 Fluorescence studies…….....76

3.2 Encapsulation of drug content and drug loading…….....77

3.3 Morphological characterization of nano-bioconjugate……..78

3.4 Average particle diameter and charge distribution measurement.....79

3.5 IR characterization of nano bio-conjugate…….....81

3.6 X-ray characterization of nano-bioconjugate…….....82

3.7 Drug release kinetic…….....83

3.8 MTT assay…….....85

3.9 Analysis of cell apoptosis…….....86

4. Conclusion……...88

5. References……...90
Chapter III……...93
1.Introduction…….……....94
2. Materials and methods…….....96
2.1 Preparation Q loaded LNs…….……...96
2.2 Surface modification of Q-LNs with maleimide…….....97
2.3 Preparation of BSA conjugated with modified Q-LNs…….....97
2.4 Scanning electron microscope (SEM) studies……....98
2.5 Particle size, size distribution, the surface charge of bioconjugate….....98
2.6 Drug encapsulation efficiency…….....99
2.7 Fourier transformed infrared spectroscopy……100
2.8 X-ray diffraction study……...100
2.9 *In vitro* release kinetic study……101
2.10 Cell culture……101
2.11 MTT assay……..101
2.12 Confocal microscopy……102
2.13 DAPI staining……102
2.14 Propidium iodide staining……102
3. Results and Discussion……..103
3.1 SEM analysis……..103
3.2 Size measurement analysis/ Encapsulation efficiency……....104
3.3 Fourier transformed infrared spectroscopy analyasis……...105
3.4 XRD analysis…….....106
3.5 Analysis of in vitro drug release kinetic…….....107
3.6 Cell viability study…….....108
3.7 Morphological analysis of MCF-7 …….....110
4.Conclusion……111
5.References……112
Chapter IV……...116
1. Introduction……117
2. Methods and Materials…….....119
2.1 Materials……119
2.2 Fabrication of LPBNPs……..120
2.3 Lactoferrin conjugation with MTX-LPBNPs……..120
2.4 Particle size analysis and assessment of surface charge ……....121
2.5 Drug encapsulation efficiency (DEE)…….....122

2.6 Scanning electron microscopy (SEM)……122
2.7 Powder X-ray diffractometry (XRD)…….....123
2.8 Fourier transformed infrared spectroscopy…….....123
2.9 Methotrexate release profile…….....123
2.10 Storage stability…….....124
2.11 Cell culture and assessment of *in vitro* cellular toxicity…….....124
2.12 Fluorescence microscopy…….....125
3. Result and Discussion ……..126
3.1 Particle size, size distribution, surface of hybrid nano-bio-conjugate……...126
3.2 Analysis of morphological surface……...129
3.3 Powder X-ray characterization of hybrid-nano-bioconjugate…….....131
3.4 Infrared spectroscopy analysis of hybrid-nano-bioconjugate.....132
3.5 *In vitro* drug dissociation kinetics……...133
3.6 Storage stability performance…….....135
3.7 Study of cell toxicity…….....136
3.8 Morphological analysis of MCF-7 cells induced with LPBNPs MTX-LPBNPs/MTX-LLPBNPs……..140
4. Conclusion…….....144
5. References ……145
Chapter V……..149
Summary and Future Work...…….149

Figure No.	Figure description	Page No.
Figure 1.1	A pictorial representation of theranostics system including diagnosis/therapeutic agent along with nanocarrier.	4
Figure 1.2	Bar-graph showing number of research papers published each year from 2010 to 2022 in the online database "Scopus", searched using the keyword ‘lipid nanocarriers and cancer theranostics’.	5
Figure 1.3	Timeline of liposome/Lipid based nanomedicine advancement. The discovery of liposomes; Enzyme entrapment into liposomes; Immunoliposomes; Procedures for liposome formation; pH-sensitive liposomes; Cationic lipids synthesized; Stealth liposomes; Transferrin receptor targeting; Temperature-sensitive liposomes; Cubosomes. The earliest approved lipid-based nanomedicine, Doxil; The earliest FDA-approved lipid - based nucleic acid (siRNA) drug Onpattro; First LNP-based mRNA vaccines for COVID-19 approved.	8
Figure 1.4	Schematic representation of five classes of lipid based nanocarriers (A) Liposomes (B) Niosomes (C) Solid lipid nanoparticles (D) Nano structured lipid carriers (E) Lipid polymer hybrid nanoparticles (LPHNs).	16
Figure 1.5	Schematic illustration of various techniques of synthesis of nano-lipid based carrier (A) Double emulsion method (B) (B)Solvent injection method (C) Microemulsion method (D) Ultrasonication method.	17
Figure 1.6	Schematic illustration of various techniques for synthesis of nano lipid-based carriers (A) Spray drying method (B)Emulsification- solvent evaporation method (C) Supercritical fluid method (D) Hot/Cold homogenization method.	22
Figure 1.7	(A)The lipid bilayer exists in two phases. The lipid head group surrounds the water channel before drying (Hexagonal phase). The lipid bilayer is packed into a two-dimensional lattice after	27

drying (Ribbon phase). (B) Orientation of lipid bilayer before and after drying in the presence and absence of sugars.

Figure 1.8 Schematic representation of ligand conjugated nanocarriers. (A)Synthesis of Tf conjugated nanocarriers and its interactions with cognate molecule. (B) The FA conjugated drug-loaded micelle and liposome and their internalization in tumor-bearing mice. (C)EDC-mediated crosslinking of HA on the surface of lipid nanocarriers. (D) RNA based aptamer and aptamer decorated nanocarrier and its interaction with the cognate receptor. 32

Figure 1.9 Schematic illustration of ligand conjugated nanocarriers. (A)NGR-conjugated thermosensitive liposome containing CPPs-DOX for detection of receptor and enhancing the DOX biodistribution. (B) Schematic representation of the synthesis of Fab' conjugated nanoparticle. Initially, reduction of anti-EGFR Fab'2 to Fab' fragment through Tris/2-carboxyethyl phosphine hydrochloride (TCEP) and generating three active thiol groups (-SH), which further react with maleimide group expressed on the nanoparticle surface. (C) EGF expressed nanocarrier for cancer theranostics of curcumin and doxorubicin in A-431 tumor cells. (D) Step by step synthesis of galactosylated conjugated drug loaded SLNs. Initially ring opening of galactose molecule and further cross-linked with amino group of stearyl amine exposed on the surface of SLNs through the EDC/NHS bioconjugate chemistry. 41

Figure 2.1 Schematic representation of the synthesis of N-acetyl D-glucosylated Q-loaded nano lipid-based carrier and its cellular internalization through receptor-mediated endocytosis. 68

Figure 2.2 Chemical reactions for N-acetyl D-glucosamine with Poly-l lysine. 70

Figure 2.3 Fluorescence spectroscopy emission spectra of the lectin-NADG complex. (a) Emission spectra of lectin reduced on gradual 77

addition of NADG. The red curve elucidates the concentration of lectin whereas the blue curve indicates a decrease in fluorescence intensity of lectin on the reaction between 5×10^{-8} and 6×10^{-7} M of NADG. (b) Logarithmic plot of the lectin-NADG system at room temperature.

Figure 2.4 Scanning electron microscopy (SEM) photograph of the nano-bio material (a) Q-NLBCs and (b) NADG-Q-NLBCs. 79

Figure 2.5 Distribution of hydrodynamic diameter in (nm) for (a) Q-NLBCs and (b) NADG-Q-NLBCs. 80

Figure 2.6 The infrared spectrum of Q-NLBCs and NADG-Q-NLBCs in the region of 4000–400 cm^{-1}. 82

Figure 2.7 X-ray diffractogram of (a) NLBCs and (b) NADG-Q-NLBCs between $2\theta = 2°$ to $2\theta = 90°$ at a scanning speed of $0.03°/second$. 83

Figure 2.8 Drug release kinetics of Q from NADG-Q-NLBCs (*in vitro*) in phosphate buffer saline for (a) Zero-order and (b) First-order at physiological pH with a significance level ($p\leq0.05^{*}$)**.** 84

Figure 2.9 Cell toxicity studies on MCF-7 cells (*in vitro*). The histograms represent the % cell viability against NLBCs, free Q, and NADG-Q-NLBCs for five different concentrations at the cell's density of 4×10^{5} cells/well. Values are reported as (mean ± standard error) and significance level as ($^{***}p< 0.001$, $^{**}p<0.01$ and $^{*}p<0.05$). All experiments were performed in triplicates. 86

Figure 2.10 Flow cytometry images of MCF-7 cells (a) Cells treated with NLBCs for 48 h and dot quadrant Q3 showing the viable cells and Q1 represents the necrotic cells (b) Cells treated with Q-NLBCs for 48 h, quadrants Q4 and Q2 showing the early and late apoptotic cells, respectively and Q1 represents the necrotic cells (c) Cells treated with NADG-Q-NLBCs for 48 h, quadrants Q4 and Q2 indicating the early and late apoptotic cells, 88

respectively and Q1 represents the necrotic cells. All experiments were performed in triplicates.

Figure 3.1 Schematic representation of the synthesis of BSA conjugated Q loaded lipid nanocarriers (LNs) and its cellular internalization through receptor mediated endocytosis. 98

Figure 3.2 Chemical reactions for maleimide functionalization and BSA conjugation. 100

Figure 3.3 SEM image of (a) void LNs (b) Q-loaded LNs (c) BSA conjugated Q-LNs. 103

Figure 3.4 FT-IR spectra in the section of 4000–400 cm^{-1} (a) void LNs(b) Q-loaded LNs (c) BSA conjugated Q-LNs. 106

Figure 3.5 X-ray diffraction image of (a) void LNs and (b) BSA-Q-loaded LNs. 107

Figure 3.6 Release kinetic studies of BSA-Q-LNs (a) Zero-order release kinetics (b) First order release kinetic. 108

Figure 3.7 The cytotoxic effect of free Q, Q-loaded LNs, and BSA conjugated Q-LNs at various concentrations of Q on MCF-7. 110

Figure 3.8 The confocal image of MCF-7, Row 1 cells treated with void LNs, Q-LNs, and BSA-Q-LNs; PI staining. Row 2 cells treated with void LNs, Q-LNs, and BSA-Q-LNs; DAPI staining. 111

Figure 4.1 Schematic illustration of the synthesis of lactoferrin conjugated MTX-LPBNPs using one-step precipitation technique and its cellular internalization through receptor-mediated endocytosis. 121

Figure 4.2 Distribution of hydrodynamic diameter in (nm) (A) MTX-LPBNPs and (B) MTX-LLPBNPs. 129

Figure 4.3 Scanning electron microscopy (SEM) photograph (A-B), and EDX images of the hybrid NPs (C-D). (A) SEM showing the MTX-LPBNPs (B) SEM showing the MTX-LLPBNPs. (C)EDX chemical mapping (inlet) and elemental composition for elements presence in MTX-LPBNPs (D) EDX chemical 130

mapping (inlet) and elemental composition for elements presence in MTX-LLPBNPs.

Figure 4.4 X-ray diffractograms of the hybrid system, scanning over 2θ = 10° to 2θ = 80° at a scanning speed of 0.03°/second using Cu Ka radiation (λ=1.54Å) (A) LPBNPs and (B) MTX-LLPBNPs. 131

Figure 4.5 The infrared spectrum of MTX-LPBNPs (Red curve) and MTX-LLPBNPs (Blue curve); was scanned on a scale of 4000 cm^{-1} to 800 cm^{-1} with a resolution of 4 cm^{-1}. 133

Figure 4.6 The MTX release profile of constructed hybrid nano-bioconjugate (LLPBNPs) was performed for 200 h. Dialysis was performed against phosphate buffer saline (pH 7.4) at room temperature using a dialysis bag. UV spectrophotometer was used to quantify the amounts of MTX concentration. Data are reported as (mean ± standard error) and significance level as ($p \leq 0.05*$) (**A**) zero-order kinetics and (**B**) first-order kinetics. 136

Figure 4.7 Cell toxicity studies of LPBNPs, MTX, MTX-LPBNPs, and MTX-LLPBNPs on MCF-7 for 24.0 h of incubation. Treatment was studied in the five groups. In the first, second, third, fourth, and fifth groups, the MTX concentration was taken 2.0, 4.0, 6.0, 8.0, and 10.0 µg/mL, respectively. In the MTX-LPBNPs and MTX-LLPBNPs formulation, a similar concentration of MTX was taken in each group. However, the LPBNPs were taken as a control in the groups. Values are reported as (mean ± standard error) and significance level as ($^{***}p< 0.001$, $^{**}p<0.01$ and $^{*}p<0.05$). 139

Figure 4.8 Cell toxicity studies of LPBNPs, MTX, MTX-LPBNPs, and MTX-LLPBNPs on MCF-7 for 48.0 h of incubation. Treatment was studied in the five groups. In the first, second, third, fourth, and fifth groups, the MTX concentration was taken 2.0, 4.0, 6.0, 8.0, and 10.0 µg/mL, respectively. In the MTX-LPBNPs and MTX-LLPBNPs formulation, a similar concentration of MTX was taken in each group. However, the LPBNPs were taken as a 140

control in the groups. Values are reported as (mean ± standard error) and significance level as ($^{***}p< 0.001$, $^{**}p<0.01$ and $^{*}p<.005$.

Figure 4.9 Fluorescence microscopy photographs of the MCF-7 after 24.0 h of treatment with LPBNPs, MTX-LPBNPs, and MTX-LLPBNPs at equivalent MTX, 10.0 (µg/mL). The fluorescence signals from the cells were illustrated in **Row 1-3** after 24.0 h of incubation. (**Row1-A**) DAPI staining, blue signals show the nucleus induced with LPBNPs. (**Row 1-B**) rhodamine-conjugated phalloidin staining, red signals show the cytoskeleton induced with LPBNPs. (**Row 1-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. (**Row 2-A**) DAPI staining, blue signals show the nucleus induced with MTX-LPBNPs. (**Row 2-B**) rhodamine-conjugated phalloidin staining, red signals show the cytoskeleton induced with MTX-LPBNPs. (**Row 2-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. (**Row 3-A**) DAPI staining, blue signals show the nucleus induced with LLPBNPs. (**Row 3-B**) rhodamine-conjugated phalloidin staining, red signals show cytoskeleton induced with MTX-LLPBNPs. (**Row 3-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. The scale bar is 50 µm for fluorescence images. 142

Figure 4.10 Fluorescence microscopy photographs of the MCF-7 after 48.0 h of treatment with LPBNPs, MTX-LPBNPs, and MTX-LLPBNPs at equivalent MTX, 10.0 (µg/mL). The fluorescence signals from the cells were illustrated in **Row 1-3** after 48.0 h of incubation. (**Row1-A**) DAPI staining, blue signals show the nucleus induced with LPBNPs. (**Row 1-B**) rhodamine-conjugated phalloidin staining, red signals show the cytoskeleton induced with LPBNPs. (**Row 1-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. (**Row 2-A**) DAPI staining, blue signals show the nucleus induced with MTX-LPBNPs. (**Row 2-B**) rhodamine-conjugated phalloidin 143

staining, red signals show the cytoskeleton induced with MTX-LPBNPs. (**Row 2-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. (**Row 3-A**) DAPI staining, blue signals show the nucleus induced with LLPBNPs. (**Row 3-B**) rhodamine-conjugated phalloidin staining, red signals show cytoskeleton induced with MTX-LLPBNPs. (**Row 3-C**) merged distribution of DAPI & rhodamine-conjugated phalloidin. The scale bar is 50 μm for fluorescence images

Table No.	Table description	Page No.
Table 1.1	List of various types of lipid-based nanocarriers.	11
Table 1.2	List of ligands and their target molecules with nanocarriers.	28
Table 2.1	Determination of amount of Q in the designednanobioconjugate.	78
Table 3.1	Particle size distribution and encapsulation efficiency.	105
Table 4.1	Particle size, size distributionzetapotential,anddrugencapsulation efficiency of MTX-LPBNPs and MTX-LLPBNPs and data represent mean ± SD, n=3.	127
Table 4.2	Storage stability performance of optimized MTX-LLPBNPs	135